Abstract: The use of a compound for preparing a pharmaceutical composition to reduce levels of TNF?, IL-6, and/or IL-1?. The compound can be used to treat immune or metabolic disorders associated with high levels of TNF?, IL-6, IL-1?, or with high levels of ACE-2 and the respective cardiac, renal and blood-pressure-related consequences, including the problems associated with treatments involving antibodies, or cell therapies, or conditions such as hypertension, myocarditis, pericarditis, coagulopathies, thrombotic, cardiovascular or renal events, or type-2 diabetes, and diseases caused by viruses such as influenza or coronavirus. The in-vivo administration of the composition of the invention affects the modulation of cytokine levels in mammals, and said cytokines are related to high levels of ACE-2, have been shown to be correlated with the severity of the disease associated with SARS-CoV-2, and have been identified as indicative markers of the prognosis of the severity thereof.

Abstract: The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: the use of a peptide compound for preparing an anticonvulsant pharmaceutical composition; and a therapeutic method. The peptide compound of the claimed pharmaceutical composition binds to and/or modulates the activity of cannabinoid receptors (CB), particularly CB1 and/or CB2, and has proven to be extremely useful as an anticonvulsant. In one embodiment, the claimed pharmaceutical composition provides excellent anticonvulsant results when administered orally to a mammal, and, in addition to other advantages and technical effects, does not entail the drawbacks arising from the use of cannabinoid substances such as cannabidiol, and provides a stronger therapeutic effect in smaller dosages and with fewer side effects.

Abstract: The present invention discloses novel non-natural and modified peptides acting as cannabinoid (CB) receptors ligands, especially CB1 and/or CB2, useful as modulators of its activity; they are also described as a kit and a process in vitro for evaluating the binding to CB receptors, uses and pharmaceutical composition for modulating the CB receptors activity. The invention covers the non-natural peptide of SeqID:1 and those having at least 70% similarity related to the same, including as achievements specialty useful of the invention the non-natural peptides of SeqID:2, SeqID:3, SeqID:4, SeqID:5, SeqID:6.

Abstract: The present invention discloses novel non-natural and modified peptides acting as cannabinoid (CB) receptors ligands, especially CB1 and/or CB2, useful as modulators of its activity; they are also described as a kit and a process in vitro for evaluating the binding to CB receptors, uses and pharmaceutical composition for modulating the CB receptors activity. The invention covers the non-natural peptide of SeqID:1 and those having at least 70% similarity related to the same, including as achievements specialty useful of the invention the non-natural peptides of SeqID:2, SeqID:3, SeqID:4, SeqID:5, SeqID:6.